Human survivability
Human survivability is R3i's thesis: whether people, institutions and nations can function under pressure. Defence, regulated AI and critical infrastructure are where that question is being decided, and where R3i executes secondary transactions — under technical complexity, regulatory constraint and fragmented ownership that make execution difficult.
We originate opportunities, establish whether they can clear, structure the transaction and coordinate execution through the appropriate legal, regulatory and capital pathways.
Pre-IPO and secondaries · The R3i Lab · Funds and vehicles
Submit a mandate Allocator enquiry
Board mandates and institutional programmes are assessed on written context.
R3i also builds companies for defence, resources and critical infrastructure. About the R3i Future Intelligence Lab ↗
United States · Europe · Singapore
01 · The problem
A company may be exceptional. A buyer may be credible. A seller may be willing.
The transaction can still fail.
Title may be unclear. Authority may be incomplete. Transfer rights may restrict the buyer. Regulation may change the route. Economics may not survive diligence. Settlement may not be executable.
R3i begins before capital moves. We ask one question first:
What must be true for this transaction to clear?
We hold this belief: the best price is rarely in the cleanest deal. It is in the one everyone else could not clear.
02 · How we work
One operating loop, applied to every mandate.
Identify proprietary opportunities, counterparties and transaction pathways where R3i has a defensible reason to participate.
Test the facts, constraints, authority, economics and regulatory route before a transaction advances.
Design the legal, economic and execution architecture required to convert interest into an executable transaction.
Coordinate the appropriate counterparties, professional advisers and regulated execution providers through closing.
Capture observed outcomes so future decisions improve rather than begin from zero.
03 · R3i decision architecture
Clearance is R3i's proprietary decision framework for determining whether a transaction can proceed, under what conditions, and what must change before it does.
Every review resolves to one of three postures, not a binary yes or no.
Clear
Proceed — with or without conditions attached.
Reroute or reprice
The opportunity is valid; the path or the economics are not.
Delay or block
Evidence is not yet sufficient, or the transaction should not proceed.
The full six-state framework, including each conditional variant, is set out on Clearance — currently being operationalised through R3i's DealDesk. Explore Clearance →
04 · Mandate
Human survivability is the thesis: whether people, institutions and infrastructure keep functioning under pressure. R3i works wherever that question is actually being decided — strategic technologies, critical systems and human health each test it in a different setting, under the same constraint.
Regulated AI · advanced compute · autonomy · defence
Energy · water · industrial infrastructure · critical materials
Health · life sciences
Sector boundaries matter less than the underlying question: what does human survivability require? Strategic technologies, critical systems and human health are not three separate bets — they are one thesis in three settings, governed by the same constraint: skilled people and regulatory clearance, not capital, decide who can take part.
The R3i model
R3i builds companies, holds them and trades in them, and clears every transaction before capital moves. Most firms do one of these. R3i does all four in defence and regulated AI, where regulation and ownership review decide who can take part.
Sovereign and pre-IPO secondary transactions in defence and regulated AI, executed through the DealDesk and underwritten by Clearance.
R3i’s venture studio builds decision-intelligence companies for defence, resources and critical infrastructure, and releases capital to each only when it clears its gate.
Lab companies are held through R3i Studio and R3i-managed vehicles. Transaction-specific vehicles are available to eligible investors through confidential documentation only.
Nothing on this page is an offer to sell, or a solicitation of an offer to buy, any security or any interest in any fund or vehicle. Information about vehicles is provided only to eligible investors, in private discussion and through definitive documentation.
05 · Evidence
R3i distinguishes principal investments, transaction mandates and advisory work, and reports them separately. We do not combine them into a single activity number.
Selected principal investments, and the basis on which each is stated, are set out on the track record. Mandate detail is available to qualified counterparties under non-disclosure agreement, following KYC and compliance clearance.
06 · Institutional architecture
Private-market complexity cannot be solved by introducing two counterparties and hoping a transaction closes.
R3i operates across a defined legal and professional architecture, with regulated securities activity conducted through appropriately authorised providers where required.
Each mandate defines R3i's role, transaction counterparties, execution pathway and any principal or related-party interest before capital moves.
07 · Human capital
Frontier technology does not fail for want of funding. It fails because there is no one to build it, run it, regulate it or maintain it. Advanced compute, autonomy, critical materials, energy systems and life sciences are all constrained by the same shortage, and capital does not resolve it.
R3i treats human capital as an investment constraint rather than a corporate-responsibility exercise. The skills a portfolio needs are identified from the assets themselves, and the pathways are built to supply them.
That work is carried out through the R3i Impact Foundation, R3i's non-profit arm, and delivered by the R3iFutureFit programme.
The people nearest the technology are furthest from the training. Pathways are mapped to the capability a sector actually lacks.
Students and early-career talent placed into mentored work at deeptech ventures, with the outcome evidenced rather than asserted.
Experienced professionals retrained and returned to work. Decades of judgement are an asset to redeploy, not a cost to retire.
Programme activity is reported separately from investment activity and is not combined into a single number.
08 · Engagement
Tell us what you want to achieve. Start with a defined objective, your role, and the context needed to assess a path forward.
For shareholders, companies, GPs and strategic counterparties with a defined private-market transaction to clear, structure or execute.
For institutional investors, family offices, sovereign capital and strategic allocators evaluating principal access.
For board mandates and institutional programmes assessed on written context rather than general access.